	US 12,329,738 B2
	Urolithin A and a composition containing same for external use in inflammations of various etiologies
Jakub Piwowarski, Umer (PL); Sebastian Granica, Warsaw (PL); Mariusz Sacharczuk, Warsaw (PL); and Marek Naruszewicz, Zalesie Gome (PL)
Assigned to MICROBIOTA MED. SP. Z O.O., Warsaw (PL)
Appl. No. 17/298,756
Filed by WARSZAWSKI UNIWERSYTET MEDYCZNY, Warsaw (PL)
PCT Filed Nov. 29, 2019, PCT No. PCT/IB2019/060337 § 371(c)(1), (2) Date Jun. 1, 2021, PCT Pub. No. WO2020/110089, PCT Pub. Date Jun. 4, 2020.
Claims priority of application No. 427944 (PL), filed on Nov. 29, 2018.
Prior Publication US 2022/0062226 A1, Mar. 3, 2022
Int. Cl. A61K 31/353 (2006.01); A61K 9/00 (2006.01); A61P 29/00 (2006.01)

CPC A61K 31/353 (2013.01) [A61K 9/0014 (2013.01); A61P 29/00 (2018.01)]

19 Claims

1. A method for the treatment or inhibition of inflammation caused by an inflammatory condition of skin and/or mucous membranes, comprising administering to a patient in need thereof a pharmaceutical composition which comprises one or more typical auxiliary substances and an active ingredient which is urolithin A or urolithin A 3,8-diacetate, wherein the pharmaceutical composition is administered by external topical administration.